Cameron CE marks subcutaneous implantable defibrillator
This article was originally published in Clinica
Cameron Health has CE marked its subcutaneous implantable defibrillator (S-ICD) device, a minimally-invasive system for use in patients at risk of sudden cardiac arrest. The system is entirely subcutaneous, with no leads in or on the heart, and imaging is not required to aid its placement, San Clemente, California-based Cameron claims. Surgical placement and presence of ICD leads within patients' hearts are associated with a significant proportion of the complications seen with the devices. Market launch in selected countries is due to begin this summer.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.